**TIPS FOR COMPLETING A PATIENT ORGANISATION SUBMISSION OF EVIDENCE TEMPLATE**

**FOR EACH ASPECT OF THE SUBMISSION:**

Describe the number of patients from whom input was obtained  
Include patient demographics (age, sex, ethnicity, disease severity)  
Exclude information on statistics and scientific published references  
Describe experiences of patients/caregivers that REFLECTS THE POPULATION WHO WILL USE THE PROPOSED DRUG  
Including specific and detailed experiences can be very helpful in providing context

---

**SECTION 1**

**INFORMATION GATHERING – Q1 and Q5**

- Describe the methods used to collect data  
- How many patients are there from each method of data collection?  
- Please include data/insights beyond what is already published in the literature.

---

**IMPACT OF CONDITION ON PATIENTS/CARERS/FAMILIES – Q2**

- How are daily functions and quality of life affected?  
- Describe the range of experiences – what is going well and what isn't?  
- Is there a financial impact?  
- Have relationships been affected?  
- How do current treatments impact on carers/families?

---

**PATIENTS EXPERIENCE WITH CURRENT STANDARD TREATMENT – Q3**

- How do patients/carer describe some of their experiences with current therapy?  
- How effective is it in reducing/controlling side effects?  
- What are the most important benefits?  
- What are the side effects which are difficult to tolerate?  
- Concerns about long-term use of current therapy.  
- Be specific about what is going well and what is not, and if experiences might vary by different subgroups of patients.  
- Are there challenges in taking it as prescribed?  
- Is the dosing modified compared to what is prescribed?

---

**WHAT ASPECTS OF LIVING WITH THEIR CONDITION DO PATIENTS NEED MOST HELP? – Q4**

- What concerns are unaddressed by current treatment?  
- Identify major areas of change you would like addressed
**SECTION 2**

**EXPECTATIONS FOR NEW TREATMENT – Q6**

- What is the anticipated impact and the desired outcomes of using this medicine compared to current therapy?
- Include any expected disadvantages or negatives with the new treatment compared to current treatment.
- How will the new treatment address unmet needs described in Q4?
- Include information on quality of life, daily functioning, side effects, etc.

**EXPERIENCES WITH NEW TREATMENT TO DATE – Q7**

- How many patients have direct experience with the drug being assessed?
- How has it affected QoL and ability to perform daily activities?
- What specific symptoms have improved?
- What are the key side effects? Include side effects that are most debilitating to quality of life, AND side effects that are tolerable.
- What concerns are unaddressed by new treatment?
- Are there any accessibility and financial implications?
- Include information about how patients with experience are accessing the drug under review.

**HOW WILL THE NEW TREATMENT ADDRESS UNMET NEEDS? – Q8**

- Will the new medicine fill any of these gaps?
- How does it fill those gaps?
- Will it make a real difference to patients’ lives?
- How strongly do you support this medicine?

**SECTION 3**

**SUMMARY – Q9**

- This section requires special consideration to ensure that you are getting across your key messages.
- Provide a 5 point summary of the KEY points.
- Include QoL data, limitations of current treatments, benefits of new treatment.

**ADDITIONAL INFORMATION – Q10**

- Are there any additional data which you believe may be helpful to the decision maker?
- Include ethical or social issues.
- Data on societal costs of the condition, costs of not treating the condition etc.

**SECTION 4**

**FUNDING FROM PHARMACEUTICAL COMPANIES – Q11**

- Full details of all funding received for EACH project within the last TWO years should be highlighted.

**DECLARATIONS FROM INDIVIDUALS INVOLVED IN THIS SUBMISSION – Q12**

- Relates to individuals that are a shareholder, director or employee of the applicant company, or are in receipt of payments direct or indirect from the applicant company.
- Mention cash/kind received by person or organisation from the applicant company, including expenses.
- Whether the interest relates to the specific medicine under consideration.
- Whether it relates to clinical trial work for the medicine under consideration.

Don’t forget to send your submission as a Word document & highlight any confidential information in yellow.